MedTrace Logo

Incretin Effect in Lean and Obese Subjects

NCT00803296 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2010-01-13

No results posted yet for this study

Summary

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Conditions

Interventions

OTHER

Oral glucose tolerance test (OGTT)

OTHER

Isoglycemic intravenous glucose infusion

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Tina Vilsbøll, MD DMSc · Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-01-31
Completion
2008-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803296 on ClinicalTrials.gov